A research team from the Laboratory of Synthetic Organic Chemistry is pioneering a new approach to drug design using computational chemistry. This technology enhances both the precision and efficiency of developing treatments for complex diseases, such as cancer, drug-resistant infections, and rapidly mutating viruses.
The process begins with molecular-level compound design, where researchers use structural simulations to study how a chemical compound binds to biological targets. These may include proteins in cancer cells, bacterial enzymes, or viral proteins. Computational methods allow scientists to accurately predict a compound’s potential, minimizing research risks and enabling the selection of only the most promising candidates before they enter lab synthesis.
Once a promising compound is identified, it is synthesized in sufficient quantities using synthetic organic chemistry techniques. These compounds then undergo biological efficacy testing at both the cellular and enzymatic levels to determine their ability to inhibit the targeted disease mechanisms.
A key strength of this method is its ability to significantly conserve time and resources. Researchers can identify high-potential compounds before full synthesis, streamlining development. Additionally, the chemical structures or functional groups of compounds can be flexibly modified, allowing the team to effectively address drug resistance and target mutations.
Beyond drug discovery, this research also contributes to the creation of sustainable synthesis processes aligned with Thailand’s unique context. It empowers Thai scientists to compete on the global scientific stage and lays the groundwork for the future production of innovative medicines that can address long-term public health challenges.
For more information: Chulabhorn Research Institute
Link: www.cri.or.th/th/
EN
CN
DE
JP
TH
